IT and Business Insights for SMB Solution Providers

Akamai Launches COVID-19 Vaccine Management Solution Built on Salesforce Vaccine Cloud

Akamai Technologies, Inc. (NASDAQ: AKAM), a trusted solution for protecting and delivering digital experiences, today announced it has developed Akamai Vaccine Edge ("Vaccine Edge") for Salesforce Vaccine Cloud, to help government agencies, healthcare organizations, businesses, nonprofits and educational institutions scale their online distribution of COVID-19 vaccines. Complementing Salesforce's recently launched Vaccine Cloud, which provides a rapid and flexible approach for managing, delivering, and administering centralized vaccine programs, Vaccine Edge helps enhance the registration and signup process when websites are under duress due to high demand.

Vaccine Edge is designed to support an enhanced customer experience by powering fast page load times regardless of the number of users registering simultaneously. When loads are too high, Vaccine Edge passes users to a waiting room to keep the site available so that the user can maintain their location in the queue. Vaccine Edge is also built with denial-of-service ("DDoS") protection to help monitor and block violators that try to take down sites by overwhelming them with targeted requests.

"Citizens need accurate, up-to-the-minute information about vaccination eligibility and the logistics of booking an appointment," said Mani Sundaram, executive vice president, global services and support and chief information officer, Akamai Technologies. "Vaccination registration websites must make this all happen — and handle sudden spikes in traffic. Vaccine Edge helps our customers provide a reliable user experience without creating more complexity for their IT teams."

Akamai's Vaccine Edge has been successfully deployed by sites serving large populations and is already providing citizens with rapid access to COVID-19 vaccine appointments. The solution is currently available [in the U.S. and Canada] to state/province and local governments as well as the next phase of vaccine distributors like major retailers, pharmacies, healthcare clinics and hospitals.    

"For most vaccine recipients, the first step in protecting themselves is scheduling an online appointment," said Meredith Flynn-Ripley, senior vice president and general manager, Salesforce Vaccine Cloud. "Akamai's Vaccine Edge solution can help provide patients with an efficient, effective, and equitable experience integrated with Salesforce."

Vaccine Edge is one of several Akamai COVID-19 initiatives in the U.S. and Canada. The company has assisted beneficiaries of the Coronavirus Aid, Relief, and Economic Security (CARES) Act with performance optimizations and virtual waiting rooms.

For more information, visit Akamai Vaccine Edge.    

Salesforce, Vaccine Cloud and others are among the trademarks of, inc.    

About Akamai

Akamai secures and delivers digital experiences for the world's largest companies. Akamai's intelligent edge platform surrounds everything, from the enterprise to the cloud, so customers and their businesses can be fast, smart, and secure. Top brands globally rely on Akamai to help them realize competitive advantage through agile solutions that extend the power of their multi-cloud architectures. Akamai keeps decisions, apps and experiences closer to users than anyone - and attacks and threats far away. Akamai's portfolio of edge security, web and mobile performance, enterprise access and video delivery solutions is supported by unmatched customer service, analytics and 24/7/365 monitoring. To learn why the world's top brands trust Akamai, visit,, or @Akamai on Twitter.


Gina Sorice
Media Relations
[email protected] 

Tom Barth
Investor Relations
[email protected]

SOURCE Akamai Technologies, Inc.

ChannelPro SMB Magazine

Get an edge on the competition

With each issue packed full of powerful news, reviews, analysis, and advice targeting IT channel professionals, ChannelPro-SMB will help you cultivate your SMB customers and run your business more profitably.